Odyssey Therapeutics, Inc.
- ODTX
- NASDAQ
- Biotechnology
- Autoimmune/Inflammatory Drugs
- Small Molecule Therapeutics
$18.38
Today +7.03%Quote Oct 19, 2026, 07:39 PM UTC
−26.06%over the last month
Max drawdown −31.9%From 1-month high −29.6%3 months −2.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Odyssey Therapeutics
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
100
Founded
2021
Market value
$883.2M
Quote Oct 19
Floor
$18.01
2.0% below price
Resistance
$19.03
3.5% above price
Price vs analyst targets
2 analysts
Lowest target
$27.00Highest target
$44.00
$27.00Highest target
$44.00
- Price $18.38
- Average target $36.60
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 99% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ODTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free